Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00.
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report).
Obesity at cancer diagnosis appeared linked to significantly poorer survival among children and adolescents, according to ...
Facundo’s lab studies B-cell biology and antibody responses, particularly B-cell receptor signaling dynamics, involvement of the cortical cytoskeleton, and more recently the role of B-cell metabolism.